| INTRODUC TI ON
The HBsAg screening in the pregnant women is a routine, and is essential for the possible therapeutic intervention of Hepatitis B virus infection in the newborns. [1] [2] [3] [4] This assay is often performed on the Sysmex system, one of the prevalent automated immunoassay analyzers in clinical laboratories. [5] [6] [7] In this system, the biotinylated-antibody is first added to the serum sample to bind HBsAg and then captured by the streptavidin-conjugated magnetic beads for further detection.
It is known that high concentration of endogenous biotin in the specimen might compete with the biotin conjugated on the antibody in immunoassays ( Figure 1A ), causing false results. 8, 9 Elevit, a multivitamin supplement that contains a substantial amount of biotin, 10, 11 is often orally taken by pregnant women for possible health improvement.
Therefore, it is possible that the HBsAg immunoassay of the blood samples from pregnant women might be affected by the Elevit that they take, giving rise to false negative results that lead to a serious misdiagnosis in clinic. We therefore investigated this in the current study. Background: The pregnant women often take Elevit as the multivitamin supplement which has a substantial amount of biotin that might potentially interfere with the HBsAg immunoassay performed by the prevalent Sysmex system in clinical laboratories. We therefore wanted to determine this, so that the therapeutic intervention on the hepatitis B virus infection during pregnancy and birth would not be missed.
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Methods:
Elevit was both serially diluted in vitro and orally taken by healthy volunteers whose blood samples were then taken at different time points. All samples were added to a serum sample with a known result of HBsAg and then measured by Sysmex. The Abbott immunoassay system was used as the control as it involves no streptavidin-biotin binding in the reagent set. Besides, the HBsAg results were compared between the pregnant women taking or not taking Elevit.
Results: Biotin at 25 ng/mL in the Elevit started to suppress the HBsAg and reached about 50% suppression at 100 ng/mL on Sysmex. In the volunteers, biotin reached the peak concentration at 2 hours. However, their blood samples showed no suppression on the HBsAg detection by Sysmex. In samples from pregnant women who took Elevit, the HBsAg results by Sysmex were highly correlated with those by Abbott (R 2 = 0.96). Comparison of the results from Sysmex between the age-and pregnancy-matched females with and without Elevit intake showed no difference.
Conclusion:
Elevit intake in pregnant women shows no significant interference with HBsAg immunoassay on Sysmex.
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| MATERIAL AND ME THODS
| Serial dilution of Elevit and the interference with HBsAg detection
One tablet of Elevit (Bayer Health Care, Berlin, Germany, contained 0.2 mg biotin) was dissolved in 100 mL saline to make 2 μg/ mL biotin, from which 100 μL was added to 0.9 mL serum with positive HBsAg to make 200 ng/mL. Meanwhile, 1 mL saline was added to 9 mL of the same serum as the diluent. A 0.5 mL of the 200 ng/mL HBsAg serum sample was then taken to make serial 2-fold dilutions in the diluent serum. This serial dilution protocol did not use saline directly as the diluent because the biotin might lose at low concentrations due to lack of carrier substances in the solution.
| Immunoassay of HBsAg by Sysmex and Abbott systems
The two systems use their own HBsAg calibrators for their reference curves independently, so their result values were therefore not directly equal. Both follow the routine sandwich immunoassay procedures. The major difference is that Sysmex uses biotinylated antibody and the streptavidin-coated magnetic particles to capture the HBsAg, while Abbott uses the antibody directly conjugated to beads. 
| Oral intake of Elevit, blood collection, and biotin measurement in healthy volunteers
| Data processing and statistical analysis
The quantitative results (unit/mL) were directly taken, or were normalized for analysis. One way ANOVA followed by Tukey post-hoc test and Student's t test were used.
| RE SULTS
The in vitro-serially diluted Elevit started to suppress the HBsAg measurement at 25 ng/mL of biotin, and reached about 50% suppression at 100 ng/mL of biotin in the Sysmex immunoassay system.
In contrast, no suppressive effect was observed in the Abbott which uses antibody directly cross-linked to magnetic beads ( Figure 1B ).
In the three volunteers who were HBsAg-negative, the biotin reached peak concentration (10.0, 21.4, and 8.4 ng/mL, respectively) at 2 hours after they orally took Elevit, and then reduced slowly at 4 and 6 hours. However, none of their blood samples at any collection time point showed suppressive effect on the HBsAg immunoassay on Sysmex (Figure 2A ). Statistical analysis of the normalized results of these three individuals showed no significant difference ( Figure 2B ).
We also collected about 50 serum samples from pregnant women who took one tablet of Elevit daily. The HBsAg immunoassay was repeated immediately on Abbott after they showed positive HBsAg results on Sysmex. Although the results from Sysmex were largely lower than those from Abbott, they showed very high correlation 
| D ISCUSS I ON
In this study, we investigated whether Elevit possibly interfered with the detection of HBsAg on the Sysmex immunoassay system.
Although Elevit showed a suppressive effect in vitro, this was not seen in vivo in healthy volunteers or the pregnant women.
The most possible reason is that the biotin from Elevit cannot reach the concentration high enough to compete with the biotin on the antibody for the streptavidin-beads. The in vitro-titrated Elevit started to suppress the HBsAg detection slightly on Sysmex at 25 ng/mL, but the peak biotin concentration in blood after Elevit intake was only about 20 ng/mL. Because each Elevit tablet only contains 200 µg biotin and the total plasma volume in an adult is 3 L approximately, the theoretical peak concentration of biotin after the intake of Elevit is no more than 66.7 ng/mL, which explained the actual peak concentration (10-20 ng/mL) in this study. Besides, the normal range of the endogenous biotin in adults is below 1 ng/mL. 12 Therefore, the oral intake of Elevit is generally insufficient to exert interference on the detection of HBsAg by the Sysmex system.
Besides, because the blood sample collection from the pregnant women is often performed in the morning after an overnight of food fasting, which has far passed the peak time point, therefore the interference from Elevit taken in the last day is minimal. We therefore conclude the intake of Elevit in pregnant women is unlikely a problem for the screening of their HBsAg in the blood samples.
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